Latest Press Releases


6 December 2017

Dr. Vassilis Tsilivakos, LOCUS MEDICUS Reproduction Immunologist, participated in the 14th Scientific Conference of the European Society of Reproductive Immunology (ESRI)

Diagnosis and treatment of unexplained infertility by 2 novel, GROUND-BREAKING methods is Now available in EUROPE!


Dr. Vassilis Tsilivakos, LOCUS MEDICUS Reproduction Immunologist, participated in the 14th Scientific Conference of the European Society of Reproductive Immunology (ESRI)

 In September 2017, the 14th Scientific Conference of the European Society of Reproductive Immunology (ESRI) Summer school took place in the home of Hippocrates, Greece, at the beautiful island of Kos (Sep 27 - Oct 2).

27 speakers from 14 countries analyzed issues related to the physiology and pathology of embryo implantation as well as the pathophysiology of miscarriages and implantation failure.

The organization of the congress by the ESRI scientific committee has been exemplary and the quality of scientific participations was of particularly high level.

LOCUS MEDICUS Reproduction Immunologist Dr. Vassilis Tsilivakos, who has been an ESRI instructor since 2009, was invited this year to give a lecture on "Placental Immunopathology".

Dr. Tsilivakos speech at ESRI Scientific Conference mainly focused on histologically distinctive alterations of the implantation site as a response to viral and microbial presence and infection.

When asked about the impact of this year’s Reproductive Immunology international congress, Dr. Tsilivakos commented that “I hope that clinicians internationally, carefully consider the new data presented here and try to correctly incorporate into their existing knowledge-base and practices the suggestions made by the expert speakers of this year’s conference, in order to be able to better help our couples straggling with infertility around the world. The Immunologic factor is of profound clinical significance and as such should be investigated and treated accordingly during the initial steps of infertility investigation preceding any IVF attempts”.

 About Locus Medicus

Locus Medicus was founded in 1997 in Greece, with the aim of creating a new type of clinic that would turn questions emerging from the medical practices into innovative solutions, through laboratory research.

Locus Medicus specializes in the investigation and treatment of unexplained infertility and recurrent miscarriages, using its clinical and research expertise, exclusive technology and internationally patented tests, to find answers where standard practices fail to succeed.

With a vast experience in genetics, cellular biology, microbiology, biochemistry and reproductive immunology, Locus Medicus has been the first clinic to introduce in Greece and on international markets the commercial use of many high-end molecular diagnostic and flow cytometry methods, as well as new medical products providing people around the world with access to specialized solutions for affordable prices.

www.locus-medicus.com

https://www.facebook.com/LocusMedicus/


Diagnosis and treatment of unexplained infertility by 2 novel, GROUND-BREAKING methods is Now available in EUROPE!

Viruses and bacteria related to infertility of unknown etiology are now easily identified with the help of 2 non-invasive, highly sensitive tests developed by Locus Medicus clinic in Greece

20 years of research have brought Locus Medicus, an innovative Greek medical clinic and research facility, to the discovery of the Hidden-C® and SPITM tests, internationally patented and published methods for the non-invasive study of female and male reproductive systems. The tests are now available for the patients all over Europe through the online platform www.locus-medicus.com.

THE HIDDEN-C TEST changes the way we look at feminine reproductive health

Unlike classical testing, the Hidden-C® Test uses menstrual blood for diagnosis of endometritis, PID (Pelvic Inflammatory Disease) and silent infertility-related infections. The test provides a deeper understanding of the feminine reproductive health, being able to identify in one sample, more than 31 microorganisms, viruses and fungi which can remain asymptomatic and may lead to infertility or to sexually transmitted infections. The test is unique as it provides a sample from the more difficult to reach upper genital tract which until now was inaccessible by non-invasive methods.

A good application of this new test is for diagnosis of asymptomatic Chlamydia. Chlamydia trachomatis is the most prevalent sexually transmitted infection in Europe and USA, and is progressively increasing. The majority of Chlamydia-infected patients remain asymptomatic and unaware of their condition until they try to become parents. In women, untreated Chlamydia trachomatis can cause PID and is associated with endometritis, ectopic pregnancy and tubal occlusion.

 Using a special sample collection kit (the “Fertility Kit”) that can be purchased on www.locus-medicus.com, women can collect a few drops of menstrual blood and send it to the clinic’s labs. Sample shipping will be automatically arranged for the patient and analysis will be carried out at the laboratories of Locus Medicus, by Real-Time PCR. The test report and a clinical interpretation of the results will be send to the patient by e-mail within 6 days after receiving the sample.

“The innovation in the Hidden-C® Test lies in the use of menstrual material, which flows through the upper and lower female genital tract, collecting cells of the shedding endometrium, as well as any microorganisms contained in cervical and vaginal fluids. As a result, menstrual blood becomes a complex source of information, which combined with the extremely high sensitivity of Real-Time PCR, exceeds >95% sensitivity for screening the endometrium for the presence of pathogens revealing hidden infections in both the upper and the lower genital tract, using a completely non-invasive way of testing,” says Doctor Vassilis Tsilivakos, Head of Research in Reproductive Medicine at Locus Medicus. Although this method seems intuitive, like any scientific innovation, Locus Medicus invested years of laboratory research in order to discover and prove its efficiency.

 EARLY PREGNANCY FAILURE AND RECURRENT MISCARRIAGES MAY ORIGINATE FROM THE SPERM

 According to the theory developed by Dr. Tsilivakos, during fertilization, vertical transmission of Herpes ½, Cytomegalovirus (CMV) or other viruses, from sperm to the embryo is possible. This process can induce proliferation and tropism of cytotoxic Natural Killer lymphocytes against cells of embryonic origin, triggering an immunological rejection. This can result in early pregnancy failure and recurrent miscarriages through the formation of “antigenic embryos” - a term invented by Dr. Tsilivakos to describe immunologically provoking embryos.

Locus Medicus laboratories propose a comprehensive investigation of sperm, to identify hidden microorganisms inside the spermatozoa, which can have a crucial influence on the future pregnancy even after a successful conception. The SPITM test (Sperm Pathogen Immunophenotyping Test) is the most sensitive test commercially available that allows the detection of intracellular pathogens which can lead to early miscarriage.

Similarly to the Hidden-C®, specimen collection for the SPITM test can take place at home after on-line order of the special sample collection kit (the “Fertility Kit”) from the clinic’s website and following the enclosed guidelines. Shipping back and forth will is automatically arranged for the patient and the analysis is then carried out at the laboratories of Locus Medicus. Test results and interpretation will be available within 6 days after receiving the sample.

The Hidden-C® Test is an internationally patented clinical test based on testing menstrual fluid for infection. (patent EP 1395670 - DETERMINING ENDOMETRIAL STATUS BY TESTING MENSTRUATION TISSUE)

The SPITM Test is an internationally patented clinical test (patent EP2831588 A1 – METHOD OF INTRACELLULAR INFECTIOUS AGENT DETECTION IN SPERM CELLS)

About Locus Medicus

Locus Medicus was founded in 1997 in Greece, with the aim of creating a new type of clinic that would turn questions emerging from the medical practices into innovative solutions, through laboratory research.

Locus Medicus specializes in the investigation and treatment of unexplained infertility and recurrent miscarriages, using its clinical and research expertise, exclusive technology and internationally patented tests, to find answers where standard practices fail to succeed.

With a vast experience in genetics, cellular biology, microbiology, biochemistry and reproductive immunology, Locus Medicus has been the first clinic to introduce in Greece and on international markets the commercial use of many high-end molecular diagnostic and flow cytometry methods, as well as new medical products providing people around the world with access to specialized solutions for affordable prices.

www.locus-medicus.com

https://www.facebook.com/LocusMedicus/

Scientific peer reviewed publication for Hidden-C:

  • Michou IV et al. (2014). Molecular investigation of menstrual tissue for the presence of Chlamydia trachomatis, Ureaplasma urealyticum and Mycoplasma hominis collected by women with a history of infertility. J Obstet Gynaecol Res. Jan;40(1):237-42.

Scientific peer reviewed publications by Locus Medicus leading to the discovery of the THE SPI™ TEST:

  • Michou et al. (2012). Herpes virus infected spermatozoa following density gradient centrifugation for IVF purposes. Andrologia. Jun;44(3):174-180.
  • Mihou et al. (2003). The Fraction of Peripheral Blood CD56 + /CD16 - /CD3 - Subpopulation on Total Natural Killer Cells as an Indication of Fertility-Infertility. Fertil Steril. 80 Suppl 2:691-7.
  • Thomas D. et al. (2004) The effect of Valacyclovir treatment on natural killer cells of infertile women. Am J. Reprod. Immunol. 51(3):248-255.
  • Thomas D. et al. (2005) Altered immunophenotypic parameters in infertile women. Possible role of herpes viremia. Am. J. Reprod. Immunol. 54(2):101-111.
  • Michou V. et al. (2012) Herpes virus infected spermatozoa following density gradient centrifugation for IVF purposes. Andrologia. 44(3):174-180.

Presentation and publication of THE SPI™ TEST on International Congresses and Proceedings:

  • Andrology, 2014,2(Suppl. 2),45-117. Method for intracellular detection of infectious pathogens in sperm cells.A.D. Gritzapis et al. Proceedings of 8th Congress of the European Academy of Andrology, 15 -17 October 2014, Barcelona, Spain.
  • J Antivirals and Antiretrovirals, 20014,6 (issue 2), 58.Intracellular detection of infectious pathogens in sperm cells. Proceedings of 4th World Congress on Virology, 6-8 October 2014, San Antonio, Texas, USA

Awards for THE SPI™ TEST

  • “Greece Innovates!” 2nd contest of Applied Research and Innovation by SEV (Hellenic Federation of Enterprises) and EUROBANK. Final phase of competition - Top10 innovations.
  • “SFEE Innovation Project” by the Hellenic Association of Pharmaceutical Companies (SFEE). Final phase of the competition - Top10 innovations.